1. Sudocetaxel Zendusortide (TH1902) triggers the cGAS/STING pathway and potentiates anti-PD-L1 immune-mediated tumor cell killing
   Michel Demeule et al, 2024, Frontiers in Immunology CrossRef
2. Synergism of BCL-2 family inhibitors facilitates selective elimination of senescent cells
   David Rysanek et al, 2022, Aging CrossRef
3. Cytokine-Induced Senescence in the Tumor Microenvironment and Its Effects on Anti-Tumor Immune Responses
   Maximilian Rentschler et al, 2022, Cancers CrossRef
4. Discovery of small molecule mechanistic target of rapamycin inhibitors as anti-aging and anti-cancer therapeutics
   Zofia Chrienova et al, 2022, Frontiers in Aging Neuroscience CrossRef
5. Cabazitaxel-loaded poly(alkyl cyanoacrylate) nanoparticles: Toxicity and changes in the proteome of breast, colon and prostate cancer cells
   Anders Øverbye et al, 2021, Nanotoxicology CrossRef
6. Senescent Tumor Cells in the Peritoneal Carcinomatosis Drive Immunosenescence in the Tumor Microenvironment
   Heidi Braumüller et al, 2022, Frontiers in Immunology CrossRef
7. A new perspective on prostate cancer treatment: the interplay between cellular senescence and treatment resistance
   Meng-Yao Xu et al, 2024, Frontiers in Immunology CrossRef
8. IL-1β is involved in docetaxel chemoresistance by regulating the formation of polyploid giant cancer cells in non-small cell lung cancer
   Song Zhao et al, 2023, Scientific Reports CrossRef
9. Enhanced target-specific delivery of docetaxel-loaded nanoparticles using engineered T cell receptors
   William J. McDaid et al, 2021, Nanoscale CrossRef